| scholarly article | Q13442814 |
| P356 | DOI | 10.1097/00008571-200003000-00001 |
| P698 | PubMed publication ID | 10761997 |
| P2093 | author name string | K Chiba | |
| K Kobayashi | |||
| T Yasumori | |||
| K Takanashi | |||
| H Tainaka | |||
| M Hosakawa | |||
| P433 | issue | 2 | |
| P304 | page(s) | 95-104 | |
| P577 | publication date | 2000-03-01 | |
| P1433 | published in | Pharmacogenetics and Genomics | Q10534561 |
| P1476 | title | CYP2C9 Ile359 and Leu359 variants: enzyme kinetic study with seven substrates | |
| P478 | volume | 10 |
| Q36835176 | A genome-wide scan for common genetic variants with a large influence on warfarin maintenance dose |
| Q28210138 | A prospective study of genetic polymorphisms in the cytochrome P-450 2C9 enzyme and the risk for distal colorectal adenoma |
| Q87079605 | Association between cytochrome P450 2C9 gene polymorphisms and colorectal cancer susceptibility: evidence from 16 case-control studies |
| Q36009999 | Bioinformatics and variability in drug response: a protein structural perspective |
| Q79227006 | Breast cancer treatment and ovarian failure: risk factors and emerging genetic determinants |
| Q28212029 | CYP2C9 allelic variants: ethnic distribution and functional significance |
| Q42235528 | CYP2C9 amino acid residues influencing phenytoin turnover and metabolite regio- and stereochemistry |
| Q34426453 | CYP2C9 genotype-dependent effects on in vitro drug-drug interactions: switching of benzbromarone effect from inhibition to activation in the CYP2C9.3 variant. |
| Q44432237 | CYP2C9 genotypes and diclofenac metabolism in Spanish healthy volunteers |
| Q46936372 | CYP2C9 genotypes and the quality of anticoagulation control with warfarin therapy among Brazilian patients |
| Q35913092 | CYP2C9 promoter variable number tandem repeat polymorphism regulates mRNA expression in human livers. |
| Q46645176 | CYP2C9*3 allelic variant is associated with metabolism of irbesartan in Chinese population |
| Q43927415 | CYP2C9*3 influences the metabolism and the drug-interaction of candesartan in vitro |
| Q30497010 | Cannabidiol as a Putative Novel Therapy for Diabetic Retinopathy: A Postulated Mechanism of Action as an Entry Point for Biomarker-Guided Clinical Development |
| Q30939373 | Characterisation of CYP2C8, CYP2C9 and CYP2C19 polymorphisms in a Ghanaian population |
| Q28362533 | Clinical relevance of genetic polymorphisms in the human CYP2C subfamily |
| Q35594567 | Clinical relevance of genetic polymorphisms in the human CYP2C9 gene |
| Q36316100 | Cloning of cytochrome P-450 2C9 cDNA from human liver and its expression in CHL cells |
| Q43844181 | Construction of Salmonella typhimurium YG7108 strains, each coexpressing a form of human cytochrome P450 with NADPH-cytochrome P450 reductase. |
| Q37219846 | Cytochrome P450 2C9 variants influence response to celecoxib for prevention of colorectal adenoma |
| Q37691210 | Cytochrome P450 2C9-CYP2C9. |
| Q37429282 | Decreased warfarin clearance associated with the CYP2C9 R150H (*8) polymorphism |
| Q35846894 | Development of an in vitro system with human liver microsomes for phenotyping of CYP2C9 genetic polymorphisms with a mechanism-based inactivator |
| Q44405606 | Differences in flurbiprofen pharmacokinetics between CYP2C9*1/*1, *1/*2, and *1/*3 genotypes |
| Q28276514 | Effect of genetic variants, especially CYP2C9 and VKORC1, on the pharmacology of warfarin |
| Q44593132 | Effect of the single CYP2C9*3 allele on pharmacokinetics and pharmacodynamics of losartan in healthy Japanese subjects |
| Q46932255 | Effective virtual screening protocol for CYP2C9 ligands using a screening site constructed from flurbiprofen and S-warfarin pockets |
| Q58796074 | Effects of polymorphic variation on the thermostability of heterogenous populations of CYP3A4 and CYP2C9 enzymes in solution |
| Q44237343 | Essential requirements for substrate binding affinity and selectivity toward human CYP2 family enzymes |
| Q51639702 | Exploring coumarin egress channels in human cytochrome p450 2a6 by random acceleration and steered molecular dynamics simulations |
| Q84265482 | Extreme sensitivity to acenocoumarol therapy in patient with both VKORC.-1639 A/A and CYP2C9*1/*3 genotypes |
| Q60182678 | Farmacogenómica clínica de CYP2C8 y CYP2C9: conceptos generales y aplicación al uso de AINE |
| Q36018001 | Frequencies of CYP2C9 polymorphisms in North Indian population and their association with drug levels in children on phenytoin monotherapy. |
| Q41096175 | Genetic Polymorphism of Cytochrome p450 (2C9) Enzyme in Iranian Baluch Ethnic Group |
| Q58581001 | Genetic Polymorphisms and In Silico Mutagenesis Analyses of CYP2C9, CYP2D6, and CYPOR Genes in the Pakistani Population |
| Q43216291 | Genetic determinants of acenocoumarol and phenprocoumon maintenance dose requirements. |
| Q33936573 | Genetic predictors of the maximum doses patients receive during clinical use of the anti-epileptic drugs carbamazepine and phenytoin |
| Q51928577 | Genotypes of the cytochrome p450 isoform, CYP2C9, and the vitamin K epoxide reductase complex subunit 1 conjointly determine stable warfarin dose: a prospective study. |
| Q90916419 | HLA-B*51:01 and CYP2C9*3 Are Risk Factors for Phenytoin-Induced Eruption in the Japanese Population: Analysis of Data From the Biobank Japan Project |
| Q38165145 | Hormonal regulation of hepatic drug biotransformation and transport systems |
| Q34660699 | How important are gender differences in pharmacokinetics? |
| Q35102211 | Implications of pharmacogenetics for individualizing drug treatment and for study design |
| Q33551882 | In vitro functional characterization of 37 CYP2C9 allelic isoforms found in Chinese Han population |
| Q43100561 | Influence of CYP2C9 and CYP2C19 genetic polymorphisms on phenytoin-induced neurological toxicity in Indian epileptic patients |
| Q44642230 | Influence of CYP2C9 genotypes on the formation of a hepatotoxic metabolite of valproic acid in human liver microsomes |
| Q34794017 | Interaction between use of non-steroidal anti-inflammatory drugs and selected genetic polymorphisms in ovarian cancer risk |
| Q36740734 | Interaction of cigarette smoking and carcinogen-metabolizing polymorphisms in the risk of colorectal polyps |
| Q41936171 | Involvement of CYP2C9 and UGT2B7 in the metabolism of zaltoprofen, a nonsteroidal anti-inflammatory drug, and its lack of clinically significant CYP inhibition potential |
| Q44218965 | Linkage between the CYP2C8 and CYP2C9 genetic polymorphisms |
| Q34474124 | Meta-analysis of cytochrome P-450 2C9 polymorphism and colorectal cancer risk |
| Q28196281 | Metabolic interactions between acetylsalicylic acid and benzene |
| Q44447379 | No major difference in inhibitory susceptibility between CYP2C9.1 and CYP2C9.3. |
| Q36402212 | Non-steroidal anti-inflammatory drugs for cancer prevention: promise, perils and pharmacogenetics |
| Q24682914 | Oxidation of celecoxib by polymorphic cytochrome P450 2C9 and alcohol dehydrogenase |
| Q34228441 | PM frequencies of major CYPs in Asians and Caucasians |
| Q35584977 | Part 2: pharmacogenetic variability in drug transport and phase I anticancer drug metabolism |
| Q36656419 | Pharmacogenetics of target genes across the warfarin pharmacological pathway |
| Q34347249 | Pharmacogenetics of warfarin elimination and its clinical implications |
| Q34458332 | Pharmacogenetics: the therapeutic drug monitoring of the future? |
| Q37378994 | Pharmacogenomic progress in individualized dosing of key drugs for cancer patients |
| Q42284291 | Pharmacokinetics of diclofenac and inhibition of cyclooxygenases 1 and 2: no relationship to the CYP2C9 genetic polymorphism in humans |
| Q40529215 | Predicting drug clearance from recombinantly expressed CYPs: intersystem extrapolation factors |
| Q33998916 | Prediction of the clearance of eleven drugs and associated variability in neonates, infants and children |
| Q33392997 | Prediction of the effects of genetic polymorphism on the pharmacokinetics of CYP2C9 substrates from in vitro data |
| Q55017025 | Presence of a single nucleotide polymorphism (RS3758581) in a boy with DRESS syndrome. |
| Q33734781 | Probing small-molecule binding to cytochrome P450 2D6 and 2C9: An in silico protocol for generating toxicity alerts |
| Q28591487 | Purification, molecular cloning, and functional expression of inducible liver acylcarnitine hydrolase in C57BL/6 mouse, belonging to the carboxylesterase multigene family |
| Q59689754 | Rapid melting curve analysis for genetic variants that underlie inter-individual variability in stable warfarin dosing |
| Q36441521 | Role of cytochrome P450 genotype in the steps toward personalized drug therapy |
| Q35078269 | Role of pharmacogenomics in individualising treatment with SSRIs |
| Q45869049 | Search for genetic determinants of sulfonylurea efficacy in type 2 diabetic patients from China. |
| Q90252988 | The Cytochrome P450 Slow Metabolizers CYP2C9*2 and CYP2C9*3 Directly Regulate Tumorigenesis via Reduced Epoxyeicosatrienoic Acid Production |
| Q37664619 | The effect of CYP2C9 and VKORC1 genetic polymorphisms on warfarin dose requirements in a pediatric population. |
| Q85776629 | The effect of polymorphic metabolism enzymes on serum phenytoin level |
| Q41118521 | The use of mechanistic DM-PK-PD modelling to assess the power of pharmacogenetic studies -CYP2C9 and warfarin as an example |
| Q30977143 | The use of pharmacokinetic and pharmacodynamic data in the assessment of drug safety in early drug development |
| Q44273797 | Tolbutamide, flurbiprofen, and losartan as probes of CYP2C9 activity in humans |
| Q37571057 | Warfarin Dosing in a Patient with CYP2C9(∗)3(∗)3 and VKORC1-1639 AA Genotypes. |
| Q44604258 | Warfarin and acenocoumarol dose requirements according to CYP2C9 genotyping in North-Italian patients. |
Search more.